Brought to you by 
TransForm enhances Lilly's lead optimization
22 Jul 2002
Executive Summary
TransForm Pharmaceuticals (technologies to rapidly identify the chemical and physical forms and formulations of drug molecules) signed a multi-year agreement to help Eli Lilly enhance its lead selection and optimization process.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- ADMET
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
TransForm enhances Lilly's lead optimization
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice